SGLT2 Inhibitors Reduce Gout Flares and CV Events Save
A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring emergency department (ED) visits or hospitalizations.
Patients with gout and type 2 diabetes were drawn from the general population (1 January 2014 to 30 June 2022) and followed for the primary outcome - recurrent gout flare (ascertained by ED visits, hospitalization, outpatient, and medication dispensing records). Patients starting SGLT2is were compared to those initiating ipeptidyl peptidase 4 inhibitors (DPP-4is).
The gout flare rate was lower among SGLT2i initiators than DPP-4i initiators (52.4 and 79.7 events per 1000 person-years, respectively), with a rate ratio (RR) of 0.66 (95% CI, 0.57 to 0.75), regardless of whether they presented as ED visits or hospitalizations.
Secondary outcomes also favored SGLT2is, including myocardial infarction (HR 0.69; CI, 0.54 to 0.88), and stroke (HR 0.81; CI, 0.62 to 1.05), but those who initiated SGLT2is had a 2 fold higher risk for genital infection (HR, 2.15 [CI, 1.39 to 3.30]).
SGLT2is use in gout may reduce recurrent gouty flares in addition to other cardiovascular benefits.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.